According to the instructions for the Nomination Committee of Immunovia, the Nomination Committee shall consist of four members, three of whom shall be appointed by the Company's largest shareholders in terms of voting rights and the fourth shall be the Chairman of the Board of Directors.

The Nomination Committee will consist of the following persons who together represent 2.88 percent of the shares and votes in the company as of September 30, 2025:

• Christer Köhler, representing Samatha Förvaltning AB;
• Anders Rylander, representing Vincent Saldell;
• Carl Borrebaeck, in his own capacity and
• Peter Høngaard Andersen, in his capacity as Chairman of the Board of Directors

The Nomination Committee will prepare proposals for shareholder approval at the 2026 Annual General Meeting, where the Nomination Committee will place particular emphasis on nominating candidates to Immunovia's Board of Directors, who can ensure that the Board possesses the appropriate skills and experience to support the company's success in 2026. The Nomination Committee will also provide its recommendation regarding a reasonable level of remuneration and other compensation to the members of the Board of Directors, based on a relevant benchmark. Furthermore, the Nomination Committee will recommend the election of, and remuneration to, the company's auditor.

"It is gratifying to have the Nomination Committee in place to begin work ahead of the 2026 Annual General Meeting. It is critical that skills and experience of Immunovia's Board members reflect the shift in Immunovias development into a commercial stage company with focus on the U.S. market." said Peter Høngaard Andersen, Chairman of the Board.

The Nomination Committee's reasoned proposals will be presented in the notice of the Annual General Meeting 2026, which will be held on 15 May 2026. Further information about the principles of the Nomination Committee and its tasks can be found at:

https://immunovia.com/home/governance/nomination-committee/

For more information, please contact:

Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com

The information was submitted for publication, through the agency of the contact persons set out above, at 10:30 CET on 15 January 2026.

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
 
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
 
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.